Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models

Hwa, Hsiao‐Lin; Kuo, Wen-Hong; Chang, Liyun; Wang, Mingyang; Tung, Tao‐Hsin; Chang, King‐Jen; Hsieh, Fon‐Jou

doi:10.1111/j.1365-2753.2007.00849.x

Cited by 48 publications

(33 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is known from the literature that TPS serum levels increased in other neoplastic diseases. Hwa et al [15] found that the TPS serum level was elevated in patients with breast cancer and showed the best predictive value among analyzed tumor markers, with a sensitivity of 80%. Assessment of TPS serum levels also appeared effective in improvement early diagnosis of recurrent ovarian cancer [14].…”

Section: Discussionmentioning

confidence: 99%

“…It has been suggested that TPS reflects the activity of tumor growth, however its clinical utility in cancer diagnosis is controversial [11,12,13,14]. In some studies, TPS has been found to be superior to CA19-9 [15,16], but inferior in others [14,17]. The aim of our study was to compare the clinical usefulness of CA19-9, neopterin and TPS serum levels in differential diagnosis of PA and CP as well as to assess their possible prognostic value.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis

et al. 2011

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis

et al. 2011

View full text Add to dashboard Cite

“…Tissue polypeptide specific antigens (TPS), which measures M 3 antigenic determinant associated with human cytokeratin 18, is a marker of tumor cell activity in contrast to markers related to tumor burden (Rydlander et al, 1996). In breast cancer management, there is an improved effectiveness can be seen when TPS is used in combination with CA15-3 (Hwa et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Correlation of Preoperative Serum Tumor Markers with Clinicopathological Features and Prognosis in Breast Cancer

Zheng¹,

Chen²,

Hu³

et al. 2012

CCO

View full text Add to dashboard Cite

Background: Serologic tumor markers such as CA15-3, CEA and TPS have been used for decades to manage patients with breast cancer. Despite the frequent use of these markers, the prognostic significance of these markers remains indeterminate. Patients and methods: We retrospectively analyzed and followed up a set of 361 patients with Stages I~III breast cancer, from January 2001 to February 2011. Serumal CA15-3 and CEA levels were measured by electrochemistry (ELC), and serumal TPS was analyzed by enzyme-linked immunosorbent assays (ELISA). We explored the relationship between preoperative serologic tumor markers and clinicopathological parameters, the correlation between CA15-3, CEA or TPS levels with overall survival, and their impact on prognosis. Results: First, at the univariate analysis, higher preoperative serum CA15-3 was significantly associated with older age of onset (≥45 years, P=0.049), and the expression of TPS was related with some traditional prognostic factors such as tumor size (P=0.030), histologic grade (P=0.001) and lymph node status (P=0.008). Second, overall survival were significantly shorter among patients with elevated preoperative serum CA15-3 (P=0.000) or TPS (P=0.038) respectively. Finally, multivariate Cox regression indicated that histological grading (P=0.028), estrogen receptor(ER) expression (P=0.001) and elevated preoperative values of CA 15-3 (P=0.015) were independent prognostic factors for overall survival. Conclusions: Our study demonstrates that higher expression of preoperative serum CA15-3 or TPS was closely correlated with clinicopathology and overall survival, and CA15-3 before treatment can be used as an independent prognostic parameter in patients with primarily breast cancer. However, serum CEA had poor correlation with clinical prognostic factors.

show abstract

“…Another example is CA15.3, which has proven useful in patients with metastatic breast cancer, when response to systemic therapy cannot be assessed (4,7). The combination of TPS, CA15-3 and IGFBP-3 increases sensitivity to 85%, and thus improves predictive ability (8). Increased CEA concentrations reflect higher risk in patients with adenocarcinomas (ACs), but not in those with squamous cell carcinomas (SCCs).…”

Section: Introductionmentioning

confidence: 99%

Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy

Zhang²,

Shu³

et al. 2008

Mol Med Rep

View full text Add to dashboard Cite

Abstract. This study evaluated the clinical utility of serum thymidine kinase 1 (STK1) in following the progression of pre-malignancies and malignancies and in monitoring the response of common carcinomas to therapy within a routine clinical setting. The STK1 concentration levels of patients with malignancies (n=224), pre-malignancies (n=10), non-tumor/ non-proliferating diseases (systemic lupus erythematosus, SLE) (n=53), benign tumors (n=20) and healthy volunteers (n=761) were determined by enhanced chemoluminescence dot blot assay. Prior to treatment, STK1 levels in the pre-malignant group alone (3.1±2.3) or in the pre-malignant and malignant groups together (2.3±1.9) were significantly higher than in the benign (1.4±0.8), SLE (1.1±0.8) or healthy volunteer (0.6±0.4) groups (p<0.01). According to ROC analysis, the STK1 assay provided a high degree of discrimination between STK1-positive pre-malignant (0.978) or pre-malignant + malignant (0.941) patients and STK1-negative healthy individuals. After varying treatments (surgery, chemotherapy, X-ray), STK1 levels increased by 40-50% during the first month, then decreased back to normal values or even lower. Following treatment, STK1 levels were significantly increased in squamous cell carcinoma (SCC) as compared to adenocarcinoma (AC) patients. In other types of malignancies, STK1 levels decreased from as early as the first month. The STK1 levels of relapsed treated patients were significantly higher (50-60%) than those of mid/long-term treated patients. In conclusion, the STK1 assay discriminated between patients with malignancies and healthy individuals very well, and is therefore potentially useful for a broad range of clinical applications. For example, it could be used for the evaluation of early tumor progression or of tumor progression during therapy in routine clinical settings, as well as for the screening of healthy individuals.

show abstract

Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models

Abstract: TPS may be useful in the detection of primary breast cancer, while sIL-2R may be useful in lymph node metastasis prediction. The combination of more than one biomarker with logistic regression model can improve the predictive sensitivity.

Cited by 48 publications

References 28 publications

Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis

Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis

Correlation of Preoperative Serum Tumor Markers with Clinicopathological Features and Prognosis in Breast Cancer

Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy

Contact Info

Product

Resources

About